10-Q: Ensysce Biosciences Faces Going Concern Doubt Amid Rising Losses

Ensysce Biosciences reported a significant increase in net loss and cash burn for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended March 31, 2026, increased to $3,556,415 from $1,945,573 in the prior year period.
• Cash and cash equivalents decreased significantly to $745,482 as of March 31, 2026, from $4,310,354 at December 31, 2025.
• The company's total stockholders' equity shifted to a deficit of $(669,012) as of March 31, 2026, from a positive equity of $2,884,750 at December 31, 2025.
• Research and development expenses increased by $1.5 million to $3.3 million for Q1 2026, primarily due to increased clinical activity for PF614.
• Federal grant revenue decreased by $0.3 million to $960,999 for Q1 2026, mainly due to the timing of research activities.
• Net cash used in operating activities more than doubled to $3.5 million for Q1 2026, compared to $1.7 million for Q1 2025.
• The company's current cash on hand is estimated to be sufficient to fund operations only through late second quarter of 2026.
• A subsequent private placement on April 6, 2026, raised $2.0 million in gross proceeds through the issuance of Series B Preferred Stock and warrants, and further increased the stated value of all outstanding Series B Preferred Stock.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the substantial increase in net loss, rapid depletion of cash, shift to a stockholders' deficit, and explicit 'going concern' doubt, despite ongoing dilutive capital raises. The short cash runway indicates severe financial pressure.

Positives

• PF614, a lead product candidate for abuse-resistant pain, is in Phase 3 clinical development, indicating progress in its core program.
• The company continues to receive federal grant funding, with $6.0 million remaining under the MPAR grant as of March 31, 2026, expected to be utilized by May 31, 2027.
• Nafamostat has completed Phase 1 clinical development, expanding the pipeline beyond opioids to infectious disease.

Negatives

• Net loss significantly increased to $3.56 million for Q1 2026, compared to $1.95 million for Q1 2025.
• Cash and cash equivalents plummeted to $0.75 million at March 31, 2026, from $4.31 million at December 31, 2025, indicating rapid cash depletion.
• The company's total stockholders' equity turned into a deficit of $(0.67) million, reflecting a deteriorating financial position.
• Net cash used in operating activities increased to $3.5 million for Q1 2026, demonstrating an accelerated cash burn rate.
• The company explicitly states substantial doubt about its ability to continue as a going concern beyond late Q2 2026 without additional financing.
• Weighted average common shares outstanding increased significantly from 1,401,144 to 6,839,385, indicating substantial dilution for existing shareholders.

Risks

• Estimates regarding expenses, revenue, capital requirements, and timing/availability of additional financing are highly uncertain and may not match actual amounts.
• The dilutive effect of recent financing transactions may negatively affect the stock price.
• There is a risk that common stock will be delisted from Nasdaq if compliance with applicable listing standards is not maintained.
• Lead product candidates PF614 and PF614-MPAR may not be successful in limiting abuse, overdose, or misuse or providing additional safety upon commercialization.
• The company relies heavily on third-party contract research organizations (CROs) for research and development activities and clinical trials, posing operational risks.
• Substantial additional funding is required to complete the development and commercialization of product candidates, which may not be available on acceptable terms or at all.
• Clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials.
• Product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
• The company may be unable to successfully market or gain market acceptance of its product candidates.
• There is a risk of overestimating the size of the target market, patient willingness to try new therapies, and physician willingness to prescribe these therapies.
• The company may be unable to obtain and maintain sufficient intellectual property protection for its investigational products or may infringe the intellectual property of others.
• The loss of key members of the management team could adversely affect operations.
• Changes in the regulatory environment could impact product development and approval timelines.
• The ability to attract and retain key scientific, medical, commercial, or management personnel is critical and uncertain.
• The company may be unable to remediate any material weaknesses or maintain effective internal controls over financial reporting.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future and requires substantial additional funding to support its operations and growth strategy. Current cash on hand is projected to fund operations only through late second quarter of 2026. Future viability is dependent on raising additional capital through equity or debt financings, or strategic collaborations, which may lead to further dilution or relinquishing valuable rights. The company anticipates increased expenses for ongoing and new clinical trials, intellectual property protection, personnel, and infrastructure as it advances product candidates towards potential commercialization.

Management Comments

• "We have incurred significant operating losses since inception, and we expect to continue to incur net losses for the foreseeable future."
• "We require substantial additional funding to support our continuing operations and pursue our growth strategy."
• "Without raising additional capital through a future offering, we believe that current cash on hand is sufficient to fund operations through late second quarter of 2026."
• "Our future viability beyond the twelve months is dependent on our ability to raise additional capital to finance our operations."

Industry Context

StockSavvy.ai notes that Ensysce Biosciences operates in the highly capital-intensive and risky clinical-stage biotech sector, specifically targeting the development of abuse-deterrent opioids and treatments for Opioid Use Disorder. The company's focus on proprietary TAAP and MPAR technologies addresses a critical public health need for safer pain management and addiction treatment. However, the significant cash burn and reliance on dilutive financing are common challenges for companies at this stage, particularly those without product revenue. The competitive landscape for pain management and addiction therapies is intense, with numerous pharmaceutical companies and biotechs vying for market share, making successful commercialization highly uncertain.

Corporate Governance

Legal Proceedings

• No pending legal proceedings against the company are expected to have a material adverse effect on cash flows, financial condition, or results of operations as of March 31, 2026, and December 31, 2025.
• A dispute with a former independent contractor over payment was resolved in April 2025, resulting in the issuance of 20,000 shares of common stock and an accrued settlement value of $0.2 million as of March 31, 2026.

Related Party Transactions

• As of March 31, 2026, a board member held a $0.2 million senior secured convertible promissory note plus accrued interest and 29,547 warrants exercisable for common stock at $23.51 per share, issued in connection with the 2023 Notes.
• On April 23, 2026 (subsequent event), the senior secured convertible promissory note payable to the board member was amended and converted into an aggregate of 508,614 unregistered shares of common stock and unregistered warrants to purchase up to 254,307 unregistered shares of common stock at an exercise price of $0.4840 per share.

Stakeholder Impact

• Shareholders face significant dilution from the substantial increase in common shares outstanding due to recent and ongoing equity and warrant issuances.
• Shareholders are exposed to the risk of common stock delisting from Nasdaq if the company fails to maintain compliance with listing standards.
• The 'going concern' doubt creates substantial uncertainty for all stakeholders regarding the company's long-term viability.
• Employees and management face potential job insecurity and operational challenges due to the company's precarious financial position and reliance on future funding.
• Creditors may face increased risk given the company's negative equity and limited cash reserves, although the 2023 Notes held by a board member have been converted.

Next Steps

• Continue preclinical studies and existing/initiate new clinical trials for PF614, PF614-MPAR, and nafamostat.
• Advance the development of other product candidates, potentially through in-licensing or acquisitions.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional clinical, quality control, medical, scientific, and other technical personnel.
• Seek regulatory approval for product candidates that successfully complete clinical trials.
• Undertake pre-commercialization activities to establish sales, marketing, and distribution capabilities for approved products.
• Expand infrastructure and facilities to accommodate a growing employee base.
• Add operational, financial, and management information systems and personnel.
• Raise substantial additional capital through private or public equity offerings, debt financings, or collaborations to fund future operations and development.
• Submit annual and final research performance progress reports to NIDA for the MPAR grant.

Key Dates

Recommendation

The company's financial health has significantly deteriorated, evidenced by a substantial increase in net loss, rapid cash depletion, and a shift to a stockholders' deficit. The explicit 'going concern' doubt, coupled with a very short cash runway (through late Q2 2026), indicates severe liquidity issues. While the company has product candidates in clinical development, the path to commercialization is long, uncertain, and highly capital-intensive. The continuous reliance on dilutive financing, as seen in the significant increase in shares outstanding and recent capital raises at low conversion/exercise prices, severely erodes shareholder value. The risks outlined are extensive and fundamental to the company's survival. Given these factors, the stock presents a high-risk profile with significant downside potential.

Keywords

Biotech, Pharmaceutical, Opioid, Pain Management, Abuse Deterrent, Overdose Protection, Clinical Stage, PF614, MPAR, TAAP, Nafamostat, SEC Filing, 10-Q, Financials, Going Concern, Dilution, Capital Raise